

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/S2BEBA129AAEN.html

Date: April 2021

Pages: 55

Price: US\$ 125.00 (Single User License)

ID: S2BEBA129AAEN

Abstracts

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Swedish Orphan Biovitrum AB (Sobi), formerly known as Biovitrum AB, is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on haemophilia, immunology, speciality care, inflammation and genetic and metabolic diseases. Sobi also manufactures and markets specialty and rare disease products for partner companies. The company has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

Apr 26,2021: Invitation - Presentation of Sobi's Q1 2021 results

Feb 18,2021: Sobi publishes report for the fourth quarter and full-year 2020

Feb 03,2021: Invitation - Presentation of Sobi"s Q4 and FY 2020 results

Dec 21,2020: Sobi appoints new Head of North America ahead of launch phase

Oct 22,2020: Sobi publishes report for the third quarter 2020

Key benefits of buying this profile include:



You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business



research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Swedish Orphan Biovitrum AB - Key Facts

Swedish Orphan Biovitrum AB - Key Employees

Swedish Orphan Biovitrum AB - Key Employee Biographies

Swedish Orphan Biovitrum AB - Major Products and Services

Swedish Orphan Biovitrum AB - History

Swedish Orphan Biovitrum AB - Company Statement

Swedish Orphan Biovitrum AB - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Swedish Orphan Biovitrum AB - Business Description

Product Category: Haematology

Overview

Performance

Product Category: Immunology

Overview

Performance

Product Category: Specialty Care

Overview

Performance

Geographical Segment: Europe

Target Markets

Performance

Geographical Segment: North America

Performance

Geographical Segment: Other

Performance

Overview

Geographical Segment: Rest of the World

Performance

Swedish Orphan Biovitrum AB - Corporate Strategy

Swedish Orphan Biovitrum AB - SWOT Analysis



SWOT Analysis - Overview

Swedish Orphan Biovitrum AB - Strengths

Swedish Orphan Biovitrum AB - Weaknesses

Swedish Orphan Biovitrum AB - Opportunities

Swedish Orphan Biovitrum AB - Threats

Swedish Orphan Biovitrum AB - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Swedish Orphan Biovitrum AB, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Apr 26, 2021: Invitation - Presentation of Sobi's Q1 2021 results

Feb 18, 2021: Sobi publishes report for the fourth guarter and full-year 2020

Feb 03, 2021: Invitation - Presentation of Sobi"s Q4 and FY 2020 results

Dec 21, 2020: Sobi appoints new Head of North America ahead of launch phase

Oct 22, 2020: Sobi publishes report for the third quarter 2020

Aug 18, 2020: Sobi appoints Dr Ravi Rao as new Head of Research & Development

Jul 16, 2020: Sobi publishes report for the second quarter 2020

Apr 29, 2020: Sobi publishes report for the first quarter 2020

Apr 17, 2020: Sobi releases new haemophilia treatment report

Apr 13, 2020: Sobi sees strong revenue and EBITA growth in the first quarter 2020

SECTION 6 – APPENDIX



Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer



List Of Tables

LIST OF TABLES

Swedish Orphan Biovitrum AB, Key Facts

Swedish Orphan Biovitrum AB, Key Employees

Swedish Orphan Biovitrum AB, Key Employee Biographies

Swedish Orphan Biovitrum AB, Major Products and Services

Swedish Orphan Biovitrum AB, History

Swedish Orphan Biovitrum AB, Subsidiaries

Swedish Orphan Biovitrum AB, Key Competitors

Swedish Orphan Biovitrum AB, Ratios based on current share price

Swedish Orphan Biovitrum AB, Annual Ratios

Swedish Orphan Biovitrum AB, Annual Ratios (Cont...1)

Swedish Orphan Biovitrum AB, Annual Ratios (Cont...2)

Swedish Orphan Biovitrum AB, Interim Ratios

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Swedish Orphan Biovitrum AB, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

Swedish Orphan Biovitrum AB, Performance Chart (2016 - 2020)

Swedish Orphan Biovitrum AB, Ratio Charts

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/S2BEBA129AAEN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/S2BEBA129AAEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970